Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Sangamo's SB-FIX gene therapy granted FDA orphan drug designation for hemophilia B

Sep. 8, 2016

Aralez Pharmaceuticals obtains rights to Zontivity in U.S. and Canada

Sep. 8, 2016

University of Montreal describes novel PAR4 antagonists

Sep. 7, 2016

Bristol-Myers Squibb presents novel PAR-4 antagonists as promising antithrombotic agents

Sep. 6, 2016

Opsona Therapeutics' OPN-305 granted FDA orphan drug status

Sep. 5, 2016

FDA accepts BLA for CSL-830

Aug. 31, 2016

Fostamatinib meets primary endpoint in the first study from the FIT phase III clinical program

Aug. 31, 2016

Japanese orphan drug designation awarded to emicizumab in hemophilia A

Aug. 29, 2016

Bristol Myers Squibb synthesizes potent and selective FXIa inhibitors

Aug. 29, 2016

Positive results for Armetheon's phase I trial of tecarfarin

Aug. 26, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...